GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

• GenSight Biologics shares resume trading today
• New financing of €10 million consisting of two tranches of €6 million and €4 million each in the form of a bond issue convertible into shares for the first tranche and an issue of new shares for the second tranche
• Immediate drawdown of the first tranche of €6 million through the issue of bonds convertible into new shares reserved for Sofinnova Partners, Invus and UPMC Enterprises
• Cash runaway extended to October 2023 after drawdown of the first tranche and to November 2023 after drawdown of the second tranche
• Renegotiation of the terms and conditions of bonds convertible into new shares with Heights with a nominal amount of €12 million
• Ongoing renegotiation of the conditions precedent to draw down the €12 million Tranche B of the EIB loan

Paris, France, August 3, 2023, 7:30am CEST — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the “Company”), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading of the Company’s shares following the signing of a €10 million financing agreement with Sofinnova Partners, Invus and UPMC Enterprises (the “Investors”) (the “Financing”) and drew down the first tranche of the Financing of €6 million (“Tranche 1”).

“We are truly grateful for the continuing support of Sofinnova Partners over the past 4 years. We are also deeply honored to see Top-Tier US healthcare investors Invus and UPMC Enterprises join this financing at a critical time for GenSight,” said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight. “This renewed trust speaks for the quality of our science and clinical data, and notably the potential for LUMEVOQ to be approved in Europe and in the US within a reasonable timeframe.“

DOWNLOAD THE FULL PRESS RELEASE